ES2133392T3 - Procedimiento para la determinacion de peptidos que correspondan a epitopos hcv importantes desde el punto de vista inmunologico. - Google Patents

Procedimiento para la determinacion de peptidos que correspondan a epitopos hcv importantes desde el punto de vista inmunologico.

Info

Publication number
ES2133392T3
ES2133392T3 ES93906490T ES93906490T ES2133392T3 ES 2133392 T3 ES2133392 T3 ES 2133392T3 ES 93906490 T ES93906490 T ES 93906490T ES 93906490 T ES93906490 T ES 93906490T ES 2133392 T3 ES2133392 T3 ES 2133392T3
Authority
ES
Spain
Prior art keywords
peptides
hcv
correspond
determination
procedure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93906490T
Other languages
English (en)
Other versions
ES2133392T5 (es
Inventor
Leys Robert De
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujirebio Europe NV SA
Original Assignee
Innogenetics NV SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8211622&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2133392(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Innogenetics NV SA filed Critical Innogenetics NV SA
Publication of ES2133392T3 publication Critical patent/ES2133392T3/es
Application granted granted Critical
Publication of ES2133392T5 publication Critical patent/ES2133392T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/13—Labelling of peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in eptitope analysis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/14011—Deltaretrovirus, e.g. bovine leukeamia virus
    • C12N2740/14022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

EL PROBLEMA TECNICO QUE SUBYACE EN LA INVENCION ES SUMINISTRAR PEPTIDOS QUE SE CORRESPONDAN CON EPITOPOS INMUNOLOGICAMENTE IMPORTANTES EN PROTEINAS DE BACTERIAS Y VIRUS, ASI COMO EL USO DE DICHOS PEPTIDOS EN COMPOSICIONES DIAGNOSTICAS O INMUNOGENICAS. LA INVENCION SE REFIERE A UN PROCESO PARA LA DETERMINACION IN VITRO DE ANTICUERPOS, EN EL QUE LOS PEPTIDOS UTILIZADOS ESTAN BIOTINILADOS, PARTICULARMENTE EN FORMA DE COMPLEJOS DE PEPTIDOS BIOTINILADOS CON ESTREPTAVIDIN O PEPTIDOS BIOTINILADOS CON AVIDIN.
ES93906490T 1992-03-06 1993-03-08 Procedimiento para la determinacion de peptidos que correspondan a epitopos hcv importantes desde el punto de vista inmunologico. Expired - Lifetime ES2133392T5 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP92400598 1992-03-06
EP92400598 1992-03-06

Publications (2)

Publication Number Publication Date
ES2133392T3 true ES2133392T3 (es) 1999-09-16
ES2133392T5 ES2133392T5 (es) 2004-12-16

Family

ID=8211622

Family Applications (2)

Application Number Title Priority Date Filing Date
ES98202777T Expired - Lifetime ES2287969T3 (es) 1992-03-06 1993-03-08 Peptidos de vih.
ES93906490T Expired - Lifetime ES2133392T5 (es) 1992-03-06 1993-03-08 Procedimiento para la determinacion de peptidos que correspondan a epitopos hcv importantes desde el punto de vista inmunologico.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES98202777T Expired - Lifetime ES2287969T3 (es) 1992-03-06 1993-03-08 Peptidos de vih.

Country Status (16)

Country Link
US (3) US5891640A (es)
EP (2) EP0891982B1 (es)
JP (2) JP3443809B2 (es)
KR (3) KR100257941B1 (es)
AT (2) ATE364621T1 (es)
AU (1) AU671623B2 (es)
BR (1) BR9305435A (es)
CA (1) CA2102301C (es)
DE (2) DE69324751T3 (es)
DK (2) DK0891982T3 (es)
ES (2) ES2287969T3 (es)
GR (1) GR3030595T3 (es)
NZ (2) NZ299048A (es)
PT (1) PT891982E (es)
SG (1) SG77551A1 (es)
WO (1) WO1993018054A2 (es)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US7413537B2 (en) * 1989-09-01 2008-08-19 Dyax Corp. Directed evolution of disulfide-bonded micro-proteins
WO1992006191A1 (en) * 1990-09-28 1992-04-16 Protein Engineering Corporation Proteinaceous anti-dental plaque agents
EP0754704B1 (en) * 1990-12-14 1999-10-06 Innogenetics N.V. Synthetic antigens for the detection of antibodies to hepatitis C virus
DE69233769D1 (de) * 1991-03-01 2009-09-24 Dyax Corp Chimäres Protein mit Mikroprotein mit zwei oder mehr Disulfidbindungen und Ausgestaltungen davon
US5773211A (en) * 1991-07-10 1998-06-30 Abbott Laboratories Differentiation of HTLV-I and HTLV-II using synthetic peptides
US6667387B1 (en) 1996-09-30 2003-12-23 N.V. Innogenetics S.A. HCV core peptides
US6709828B1 (en) 1992-03-06 2004-03-23 N.V. Innogenetics S.A. Process for the determination of peptides corresponding to immunologically important epitopes and their use in a process for determination of antibodies or biotinylated peptides corresponding to immunologically important epitopes, a process for preparing them and compositions containing them
DE69331266T2 (de) * 1992-05-29 2002-08-08 Florey Howard Inst Oligonucleotid-polyamide konjugate
IT1270941B (it) * 1993-05-12 1997-05-26 Sorin Biomedica Spa Peptidi di hcv e loro usi.
EP0697888B1 (en) 1993-05-12 2003-09-17 Chiron Corporation Conserved motif of hepatitis c virus e2/ns1 region
EP0729973A4 (en) * 1993-10-29 1998-12-30 Srl Inc AN ANTIQUE PEPTIDE COMPOUND AND IMMUNOASSAY PROCEDURE
DE69433971T2 (de) 1993-11-04 2005-09-08 Innogenetics N.V. Von menschlichen T-Zellen immunodominante Epitopen des Virus der C-Hepatitis
AU1443695A (en) * 1993-12-20 1995-07-10 Abbott Laboratories Differentiation of htlv-i and htlv-ii using synthetic peptides
US5709995A (en) 1994-03-17 1998-01-20 The Scripps Research Institute Hepatitis C virus-derived peptides capable of inducing cytotoxic T lymphocyte responses
GB9410044D0 (en) * 1994-05-19 1994-07-06 Int Murex Tech Corp Assay
US6303574B1 (en) 1994-07-22 2001-10-16 The University Of North Carolina At Chapel Hill Scr SH3 binding peptides and methods of isolating and using same
US6184205B1 (en) * 1994-07-22 2001-02-06 University Of North Carolina At Chapel Hill GRB2 SH3 binding peptides and methods of isolating and using same
WO1996003423A1 (de) * 1994-07-25 1996-02-08 Boehringer Mannheim Gmbh Hapten-markierte peptide
CN1114106C (zh) * 1994-07-25 2003-07-09 罗切诊断学有限公司 金属螯合物标记的肽及其制备方法
SG71728A1 (en) * 1994-07-29 2000-04-18 Innogenetics Nv Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use
JP3665371B2 (ja) * 1994-08-31 2005-06-29 株式会社先端生命科学研究所 Ｃ型肝炎ウイルス感染又はグループ判定のためのエピトープキメラ抗原ペプチド、その製法、及びそれを使用する感染又はグループ判定法
US6399294B1 (en) * 1994-10-20 2002-06-04 Institut Pasteur Nucleotide sequences of HIV-1 type (or subtype) O retrovirus antigens
AU780017B2 (en) * 1994-10-20 2005-02-24 Institut Pasteur Nucleotide sequences of HIV-1 type (or subtype) O retrovirus antigens
FR2731225B1 (fr) * 1995-03-03 2003-10-31 Pasteur Institut Peptides de glycoproteine transmembranaire d'enveloppe et de proteine de capside du retrovirus humain du type hiv-1 et peptides presentant avec eux une parente immunologique
DE19504302A1 (de) * 1995-02-09 1996-08-14 Boehringer Mannheim Gmbh Methode zur serologischen Typisierung mittels typspezifischer Antigene
DE19505262C2 (de) * 1995-02-16 1998-06-18 Behring Diagnostics Gmbh Retrovirus aus der HIV-Gruppe und dessen Verwendung
AU5100696A (en) * 1995-03-02 1996-09-18 Akzo Nobel N.V. Specific hiv-1 group o antigens
US6309820B1 (en) 1995-04-07 2001-10-30 University Of North Carolina At Chapel Hill Polypeptides having a functional domain of interest and methods of identifying and using same
JPH11509172A (ja) 1995-04-07 1999-08-17 サイトジェン・コーポレーション 目的の機能ドメインを有するポリペプチドおよびそれの同定および利用法
WO1996034013A1 (fr) * 1995-04-28 1996-10-31 Srl, Inc. Compose peptidique antigenique et methode de dosage immunologique
US6110465A (en) * 1995-06-07 2000-08-29 The United States Of America As Represented By The Department Of Health And Human Services Nucleotide and deduced amino acid sequences of hypervariable region 1 of the envelope 2 gene of isolates of hepatitis C virus and the use of reagents derived from these hypervariable sequences in diagnostic methods and vaccines
JPH0967395A (ja) * 1995-08-31 1997-03-11 S R L:Kk 抗原ペプチド化合物および免疫学的測定方法
DE19534988A1 (de) * 1995-09-21 1997-03-27 Forssmann Wolf Georg Verfahren zur Herstellung und Anwendung synthetischer, biotinylierter Peptide
JP2002171972A (ja) * 1996-10-14 2002-06-18 Chemo Sero Therapeut Res Inst 肝炎ウイルスエピトープ
US6270777B1 (en) * 1996-12-20 2001-08-07 University Technologies International Inc. Conserved metalloprotease epitopes
FR2765688B1 (fr) 1997-07-04 1999-09-10 Pasteur Institut Reactif de detection et de suivi des infections provoquees par le virus d'epstein-barr et ses applications
WO1999024466A2 (en) 1997-11-06 1999-05-20 Innogenetics N.V. Multi-mer peptides derived from hepatitis c virus envelope proteins for diagnostic use and vaccination purposes
EP0947525A1 (en) * 1998-03-27 1999-10-06 Innogenetics N.V. Epitopes in viral envelope proteins and specific antibodies directed against these epitopes: use for detection of HCV viral antigen in host tissue
CA2343934A1 (en) 1998-09-25 2000-04-06 The Children's Medical Center Corporation Short peptides which selectively modulate the activity of protein kinases
SE9903031D0 (sv) * 1999-08-27 1999-08-27 Eurodiagnostica Ab Peptide mixture and vaccine against a chronic viral infection
IT1310160B1 (it) * 1999-09-03 2002-02-11 Invicta S P A Zaino con schienale provvisto di lamina elastica
JP2003064096A (ja) * 2001-08-29 2003-03-05 Mitsubishi Kagaku Bio-Clinical Laboratories Inc Ｃ型肝炎ウイルス特異的細胞障害性ｔ細胞認識エピトープ
CA2462651A1 (en) * 2001-10-05 2003-04-17 Novozymes A/S Kit for predicting binding of a specific antibody to a potential immunogen and method of screening
CN100479859C (zh) * 2002-03-20 2009-04-22 厦门大学 一种针对靶的空间变构现象筛选可抑制和/或激活所述靶生物活性的物质的方法
WO2004092724A2 (en) * 2003-04-11 2004-10-28 The Government Of The United States Of America As Represented By The Secretary, Department Of Health Multiple antigenic peptide assay for detection of hiv or siv type retroviruses
US7604804B2 (en) 2004-02-09 2009-10-20 University Of Maryland Biotechnology Institute Enhancing anti-HIV efficiency through multivalent inhibitors targeting oligomeric gp120
US20070073039A1 (en) * 2005-09-29 2007-03-29 Chisari Francis V Peptides that inhibit viral infections
US8865398B2 (en) * 2006-09-01 2014-10-21 Abbott Laboratories Combination hepatitis C virus antigen and antibody detection method
EP2196804A4 (en) * 2007-10-05 2010-09-15 Kaneka Corp MARKED PEPTIDE WITH IMMOBILOBULIN BINDING ACTIVITY AND / OR AN IMMUNE LOBULIN COMPLEX AND METHOD FOR DETECTING OR REVIEWING IMMUNE LOBULIN WITH THE AID OF PEPTIDE
US8748130B2 (en) * 2008-09-02 2014-06-10 Antigen Express, Inc. Human papillomavirus / Ii-Key hybrids and methods of use
FR2984328B1 (fr) 2011-12-20 2016-12-30 Bio-Rad Innovations Procede de detection d'une infection par le virus de l'hepatite c
CN105189465B (zh) 2013-03-21 2019-02-26 赛诺菲-安万特德国有限公司 合成含有乙内酰脲的肽产物
ES2624961T3 (es) 2013-03-21 2017-07-18 Sanofi-Aventis Deutschland Gmbh Síntesis de productos de péptido que contienen imida cíclica
EP2989120A4 (en) 2013-04-25 2017-04-19 Carmel-Haifa University Economic Corp. Synthetic anti-inflammatory peptides and use thereof
WO2015097077A2 (en) 2013-12-27 2015-07-02 F. Hoffmann-La Roche Ag Systemic discovery, maturation and extension of peptide binders to proteins
AU2016251501A1 (en) 2015-04-20 2017-10-19 F. Hoffmann-La Roche Ag Specific peptide binders to proteins identified via systemic discovery, maturation and extension process

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1984003506A1 (en) * 1983-03-08 1984-09-13 Commw Serum Lab Commission Antigenically active amino acid sequences
US5075211A (en) * 1986-03-26 1991-12-24 Genetic Systems Corporation Synthetic antigen for the detection of AIDS-related disease
US4833071A (en) * 1987-01-09 1989-05-23 United Biomedical, Inc. Peptide composition as anitgen for detection of antibodies to HTLV-I, as a vaccine for ATL and methods therefor
EP0278940A3 (en) * 1987-01-30 1988-12-07 Smithkline Biologicals S.A. Hepatitis b virus surface antigens and hybrid antigens containing them
AU629528B2 (en) * 1988-01-27 1992-10-08 Biochem Pharma Inc. Synthetic peptides and mixtures thereof for detecting hiv antibodies
DE3853422T2 (de) * 1988-06-09 1995-10-26 Innogenetics Nv HIV-3-Retrovirus und seine Verwendung.
DE3901857A1 (de) * 1989-01-23 1990-07-26 Boehringer Mannheim Gmbh Verfahren zur bestimmung von hiv 2 antikoerpern
SU1612264A1 (ru) * 1989-03-01 1990-12-07 Институт биоорганической химии им.М.М.Шемякина Способ твердофазного иммуноферментного определени антител к вирусу иммунодефицита человека и меченный биотином синтетический пептид дл его осуществлени
KR0185373B1 (ko) * 1989-03-17 1999-05-01 로버트 피. 블랙버언 Hcv 폴리단백질에서 유래되는 hcv 아미노산 서열 부분을 포함하는 폴리펩티드 및 그 사용
US5120662A (en) * 1989-05-09 1992-06-09 Abbott Laboratories Multilayer solid phase immunoassay support and method of use
DE69129207T2 (de) * 1990-01-16 1998-10-08 Orgenics Ltd Peptide, von Virus-HIV-Hüllen-Glycoproteinen abstammend, deren Verwendung zum Nachweis einer Infektion dieser Viren und für die Impfung gegen AIDS
KR940000755B1 (ko) * 1990-02-16 1994-01-29 유나이티드 바이오메디칼 인코오포레이티드 Hcv에 대한 항체 검출, hcv 감염의 진단 및 백신으로서의 그 예방에 특히 적합한 합성 펩티드
EP0445801A3 (en) * 1990-03-08 1992-07-01 Kuraray Co., Ltd. Peptide and its use
EP0448095A1 (en) * 1990-03-21 1991-09-25 Wolf, Hans Joachim, Prof. Dr. Subregion of the retroviral ENV protein, DNA sequences encoding it and compositions for the diagnosis, prevention or therapy of retrovirus infections
CA2047792C (en) * 1990-07-26 2002-07-02 Chang Y. Wang Synthetic peptides specific for the detection of antibodies to hcv, diagnosis of hcv infection and prevention thereof as vaccines
DK0770679T4 (da) * 1990-11-03 2010-05-10 Siemens Healthcare Diagnostics HCV-specifikke peptider, sammensætninger dertil og anvendelse deraf
EP0754704B1 (en) * 1990-12-14 1999-10-06 Innogenetics N.V. Synthetic antigens for the detection of antibodies to hepatitis C virus
US5574132A (en) * 1991-04-05 1996-11-12 Biochem Immunosystems Inc. Peptides and mixtures thereof for detecting antibodies to hepatitis C virus (HCV)
AU648912B2 (en) * 1991-06-13 1994-05-05 Dade International Inc. Immunoassay for non-A non-B hepatitis
ES2126620T5 (es) 1992-10-06 2010-05-21 Siemens Healthcare Diagnostics Products Gmbh Retrovirus del grupo de los vih y su utilizacion.

Also Published As

Publication number Publication date
JP3443809B2 (ja) 2003-09-08
ES2287969T3 (es) 2007-12-16
BR9305435A (pt) 1994-12-27
JPH06505806A (ja) 1994-06-30
EP0891982B1 (en) 2007-06-13
EP0589004B1 (en) 1999-05-06
DE69324751D1 (de) 1999-06-10
DE69334148D1 (de) 2007-07-26
PT891982E (pt) 2007-07-27
ATE179716T1 (de) 1999-05-15
DE69324751T2 (de) 2000-01-13
US5891640A (en) 1999-04-06
GR3030595T3 (en) 1999-10-29
WO1993018054A2 (en) 1993-09-16
EP0589004A1 (en) 1994-03-30
DK0891982T3 (da) 2007-09-03
SG77551A1 (en) 2005-04-28
KR100257941B1 (ko) 2000-06-01
CA2102301C (en) 2008-09-16
JP2004002379A (ja) 2004-01-08
KR20030096423A (ko) 2003-12-31
DK0589004T3 (da) 1999-11-15
EP0891982A2 (en) 1999-01-20
KR100259223B1 (en) 2000-06-15
EP0589004B2 (en) 2004-05-06
EP0891982A3 (en) 2000-04-12
AU671623B2 (en) 1996-09-05
ES2133392T5 (es) 2004-12-16
ATE364621T1 (de) 2007-07-15
AU3746393A (en) 1993-10-05
US6165730A (en) 2000-12-26
DE69334148T2 (de) 2008-02-21
WO1993018054A3 (en) 1994-02-17
US6210903B1 (en) 2001-04-03
DK0589004T4 (da) 2004-08-16
NZ249838A (en) 1996-10-28
NZ299048A (en) 1998-09-24
DE69324751T3 (de) 2005-03-17
CA2102301A1 (en) 1993-09-07

Similar Documents

Publication Publication Date Title
ES2133392T3 (es) Procedimiento para la determinacion de peptidos que correspondan a epitopos hcv importantes desde el punto de vista inmunologico.
DE3876496D1 (de) Synthetisches peptid-antigen fuer nachweis von hiv-2-infektionen.
NO872473L (no) Peptidblanding og fremgangsmaate ved paavisning av antistoffer mot htlv-iii.
NO169844C (no) Htlv-iii (env)-peptider
SE8704185D0 (sv) Nya peptider, artificiella antigener och immunoanalystestsatser
KR900700507A (ko) Htlv-1 감염 검출용 합성 펩티드 항원
EP0284587A3 (en) Synthetic peptide antigens for the detection of hiv-1 infection
DE69013950D1 (de) Monoklonaler Antikörper zur Unterscheidung HIV-2-seropositiver von HIV-1-seropositiven Individuen.
AU2314088A (en) Method for rapid and sensitive detection of igm retroviral antibodies
AU608413B2 (en) Mouse monoclonal antibody (5-21-3) to human immunodeficiency virus gp41 protein
DE59309950D1 (de) HCV Peptidantigene und Verfahren zur Bestimmung von HCV
SE9000595D0 (sv) New peptides, diagnostic antigens and an immunoassay method
GR3033885T3 (en) Synthetic antigens for the detection of aids-related disease caused by LAV-2.
SE9101863D0 (sv) Peptider, diagnostiskt antigen, vaccinkomposition och foerfarande foer selektering av hiv-stammar

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 589004

Country of ref document: ES